期刊
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
卷 51, 期 3, 页码 817-829出版社
OXFORD UNIV PRESS
DOI: 10.1093/ije/dyab274
关键词
Pancreatic cancer; proteomics; biomarkers; risk prediction; early diagnosis
资金
- Kadoorie Charitable Foundation, Hong Kong
- UK Wellcome Trust [088158/Z/09/Z, 104085/Z/14/Z]
- Chinese Ministry of Science and Technology [2011BAI09B01]
- Chinese National Natural Science Foundation [81390541]
- British Heart Foundation Intermediate Clinical Research Fellowship [FS/18/23/33512]
- National Institute for Health Research Oxford Biomedical Research Centre
- China Postdoctoral Science Foundation [2019TQ0008, 2020M670071]
- Cancer Research UK programme grant [C8221/A29017]
- NDPH Pump Priming Award
- Pancreatic Cancer UK [A102016RIFProfZChen]
- Cancer Research UK Oxford Centre [C552/A17720]
Several plasma proteins were found to be associated with the risk of subsequent diagnosis of pancreatic cancer, potentially serving as biomarkers for early detection and prediction. While there was only a small increase in discrimination for long-term risk, the clinical utility of these proteins warrants further investigation.
Background Pancreatic cancer has a very poor prognosis. Biomarkers that may help predict or diagnose pancreatic cancer may lead to earlier diagnosis and improved survival. Methods The prospective China Kadoorie Biobank (CKB) recruited 512 891 adults aged 30-79 years during 2004-08, recording 702 incident cases of pancreatic cancer during 9 years of follow-up. We conducted a case-subcohort study measuring 92 proteins in 610 cases and a subcohort of 623 individuals, using the OLINK immuno-oncology panel in stored baseline plasma samples. Cox regression with the Prentice pseudo-partial likelihood was used to estimate adjusted hazard ratios (HRs) for risk of pancreatic cancer by protein levels. Results Among 1233 individuals (including 610 cases), several chemokines, interleukins, growth factors and membrane proteins were associated with risk of pancreatic cancer, with adjusted HRs per 1 standard deviation (SD) of 0.86 to 1.86, including monocyte chemotactic protein 3 (MCP3/CCL7) {1.29 [95% CI (confidence interval) (1.10, 1.51)]}, angiopoietin-2 (ANGPT2) [1.27 (1.10, 1.48)], interleukin-18 (IL18) [1.24 (1.07, 1.43)] and interleukin-6 (IL6) [1.21 (1.06, 1.38)]. Associations between some proteins [e.g. matrix metalloproteinase-7 (MMP7), hepatocyte growth factor (HGF) and tumour necrosis factor receptor superfamily member 9 [TNFRSF9)] and risk of pancreatic cancer were time-varying, with higher levels associated with higher short-term risk. Within the first year, the discriminatory ability of a model with known risk factors (age, age squared, sex, region, smoking, alcohol, education, diabetes and family history of cancer) was increased when several proteins were incorporated (weighted C-statistic changed from 0.85 to 0.99; P for difference = 4.5 x 10(-5)), although only a small increase in discrimination (0.77 to 0.79, P = 0.04) was achieved for long-term risk. Conclusions Several plasma proteins were associated with subsequent diagnosis of pancreatic cancer. The potential clinical utility of these biomarkers warrants further investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据